TEXT D In the 1950s, the
development of antipsychotic drugs called neuroleptics(抑制精神病药物)radically changed
the clinical outlook for patients in mental institutions who had previously been
considered hopelessly psychotic. Daily medication controlled delusions and
made psychotherapy possible. Many who otherwise might never have left
institutions returned to society. Now physicians have learned that there is a
price to be paid for these benefits. Approximately 10 to 15 percent of patients
who undergo long-term treatment with antipsychotic drugs develop a cluster of
symptoms called tardive dyskinesia(迟发性运动障碍 ), the most common symptoms of which
are involuntary repetitive movement of the tongue, mouth, and face, and
sometimes the limbs and trunk. Neuroleptic drugs interfere with
the action of dopamine (多巴胺), an important neurotransmitter in the brain, by
binding to the dopamine receptors of nerve cells, and dopamine is a prime
suspect in the pathophysiology of schizophrenia. Large doses of drugs such as
amphetamines(苯丙胺), which stimulate secretion of dopamine, produce a psychosis
resembling schizophrenia. Reducing the activity of this neurotransmitter
alleviates the delusions that cause psychotic behavior. Although the inhibition
of dopamine activity can control psychotic behavior, researchers now believe
that the central nervous system of some patients adapts to long-term therapy by
increasing the number of specific dopamine binding sites. The net result is
dopamine hypersensitivity which is correlated with the subsequent appearance of
tardive dyskinesia. The risk of developing tardive dyskinesia is
not so great that doctors have considered abandoning the use of antipsychotic
drugs. Patients generally are bothered only slightly by the physical side
effects, though the abnormal movements are troubling and may hinder social
adjustment. Additionally, early diagnosis and prompt discontinuation of the
neuroleptics might decrease the incidence of the movement disorders.
Unfortunately, without neuroleptic drugs, psychotic behavior returns. So
researchers have tried to achieve a satisfactory balance between the two
effects, lowering dosage to a level that minimizes movement disorders yet
control psychosis. In a five-year study of twenty-seven psychiatric patients
treated with neuroleptics representing all classes of antipsychotic drugs,
researchers attempted to decrease drug doses to their lowest effective levels.
Patient responses suggested that low to moderate doses of antipsychotic drugs
could control psychoses just as well as high doses, and tardive dyskinesia
symptoms stabilized and gradually diminished or completely
disappeared. The fact that psychoses can be controlled at the
same time that tardive dyskensia symptoms are reduced suggests that a drug more
specifically affecting the mechanism of psychoses might not cause movement
disorders. Sulpiride, a drug not available in the United States but widely used
in Europe, where it was developed, may be one such alternative. The drug
selectively blocks D-2 dopamine receptors, perhaps especially those in the
limbic area of the brain, which is involved in emotion and behavior. It
does not adversely affect the adenylate ( 腺苷酸) cyclase ( 环化酶 )-linked D -1
dopamine receptors. Sulpiride has proven effective in the short term, but
whether it suppresses tardive dyskenesia over a long period of treatment is not
yet known. It can be inferred that the primary danger of tardive dyskinesia is the______.
A.psychological effect on the patient B.long-term therapeutic use of drugs C.addiction of a patient to dopamine D.physical injuries caused by violent muscle spasms